AstraZeneca (United States)

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine ki...

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Profiling tumor bacteria Bacteria are well-known residents in human tumors, but whether their presence is advantageous to the tumors or to the bacteria themselves has been uncle...

Olaparib for Metastatic Castration-Resistant Prostate Cancer

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...

Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

Kinase inhibitors constitute an important new class of cancer drugs, whose selective efficacy is largely determined by underlying tumor cell genetics. We established a high-thro...